Pharmacokinetics of acebutolol enantiomers after intravenous administration of racemate in a rat model: A dosing range comparison

被引:0
|
作者
Mostafavi, SA [1 ]
Foster, RT [1 ]
机构
[1] UNIV ALBERTA,FAC PHARM & PHARMACEUT SCI,EDMONTON,AB T6G 2N8,CANADA
关键词
acebutolol; linearity; pharmacokinetics; enantiomer; rat;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Acebutolol (AC) is a chiral P-adrenergic blocking drug, possessing intrinsic sympathomimetic activity (ISA), and is useful clinically as the racemate in treating hypertension. Utilizing a stereospecific high-performance liquid chromatographic (HPLC) assay, the enantiomeric disposition of AC and its major metabolite diacetolol (DC) are reported after intravenous administration of single 5, 15, 30, and 50 mg kg(-1) doses of racemate to male Sprague-Dawley rats. The mean area under the plasma concentration versus time curve (AUC) values display a linear relationship with respect to the administered dose. No statistical differences are observed in apparent volume of distribution (V-d), terminal elimination half-life (t(1/2)), total body clearance (CW, or renal clearance (Cl,) with respect to dose administered. Generally, R-S ratios for AUC following AC administration are statistically different from unity (p < 0.05). However, for the 50 mg kg(-1) doses the R-S ratio for AUC is not statistically different from one. For DC, the plasma disposition is nonstereoselective in plasma. The amount of R-DC recovered in urine, however, was greater than that of the antipode (R:S = 1.92 +/- 0.29). This study suggests that the enantiomeric disposition of intravenous AC is linear within the investigated range of 5-50 mg kg(-1) racemate in rats. (C) 1997 by John Wiley & Sons, Ltd.
引用
收藏
页码:397 / 408
页数:12
相关论文
共 50 条
  • [21] PHARMACOKINETICS OF KETOPROFEN ENANTIOMERS AFTER DIFFERENT DOSES OF THE RACEMATE
    GEISSLINGER, G
    MENZEL, S
    WISSEL, K
    BRUNE, K
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 40 (01) : 73 - 75
  • [22] Pharmacokinetics of thiopental and pentobarbital enantiomers after intravenous administration of racemic thiopental
    Nguyen, KT
    Stephens, DP
    McLeish, MJ
    Crankshaw, DP
    Morgan, DJ
    ANESTHESIA AND ANALGESIA, 1996, 83 (03): : 552 - 558
  • [23] PHARMACOKINETICS OF ETODOLAC ENANTIOMERS IN THE RAT AFTER ADMINISTRATION OF PHENOBARBITAL OR CIMETIDINE
    BROCKS, DR
    JAMALI, F
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1992, 17 (04) : 293 - 299
  • [24] Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model
    Marchettini, P
    Stuart, OA
    Mohamed, F
    Yoo, D
    Sugarbaker, PH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (06) : 499 - 503
  • [25] Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model
    Pierre Marchettini
    Anthony O. Stuart
    Faheez Mohamed
    Dal Yoo
    Paul H. Sugarbaker
    Cancer Chemotherapy and Pharmacology, 2002, 49 : 499 - 503
  • [26] Pharmacokinetics of ethopropazine in the rat after oral and intravenous administration
    Maboudian-Esfahani, M
    Brocks, DR
    BIOPHARMACEUTICS & DRUG DISPOSITION, 1999, 20 (03) : 159 - 163
  • [27] PHARMACOKINETICS AND PHARMACODYNAMICS OF PHYSOSTIGMINE IN THE RAT AFTER INTRAVENOUS ADMINISTRATION
    SOMANI, SM
    KHALIQUE, A
    DRUG METABOLISM AND DISPOSITION, 1987, 15 (05) : 627 - 633
  • [28] Pharmacokinetics of Isorhynchophylline in Rat Plasma after Intravenous Administration
    Ren, Ke
    Jin, Yue
    Wang, Xianqin
    Wei, Zhen
    LATIN AMERICAN JOURNAL OF PHARMACY, 2019, 38 (05): : 991 - 995
  • [29] PHARMACOKINETICS OF THE ENANTIOMERS OF FELODIPINE IN THE DOG AFTER ORAL AND INTRAVENOUS ADMINISTRATION OF A PSEUDORACEMIC MIXTURE
    ERIKSSON, UG
    HOFFMANN, KJ
    SIMONSSON, R
    REGARDH, CG
    XENOBIOTICA, 1991, 21 (01) : 75 - 84
  • [30] Pharmacokinetics of ofloxacin enantiomers after intravenous administration for antibiotic prophylaxis in biliary surgery
    Gascón, AR
    Campo, E
    Hernández, RM
    Calvo, B
    Errasti, J
    Muñoz, JLP
    JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (08): : 869 - 874